TRT Aveed denied as not medically necessary by Humana?

Humana's specific coverage criteria for trt aveed are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Aveed for Medical Necessity

Humana's medical-necessity denial means their reviewers determined that the clinical documentation submitted with the prior authorization did not sufficiently demonstrate that Aveed (testosterone undecanoate long-acting injection) meets their clinical criteria for coverage. This is among the most common denial types for testosterone replacement therapy — and among the most successfully appealed — because it turns entirely on whether the right documentation was presented, not on whether the drug is appropriate.

## Why This Denial Is Appealable

Medical-necessity denials must be based on Humana's written coverage criteria applied to the specific clinical facts of your case. If those criteria are met and the documentation proves it, the denial must be reversed. In many cases, denials happen because the initial authorization request lacked key chart elements that Humana requires. The appeal is your opportunity to submit a complete record.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial. Humana must respond within 30 days for standard review (72 hours for expedited).
• External review (ACA §2719 / ERISA §503): After an adverse internal determination, you have approximately 4 months to request binding external review by an independent organization. External reviewers apply clinical standards independently of Humana's internal guidelines.
• Expedited process: If delay poses serious health risk, request expedited internal and external review; Humana must respond within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation — Physician chart notes establishing the diagnosis of hypogonadism, including symptom onset, duration, and clinical history. Obtain the relevant laboratory results with reference ranges from the ordering lab; do not rely on a summary — the actual report matters. 2. Prior treatment history — Documentation of any prior testosterone formulations or other treatments tried, including dates, doses as recorded in the chart, and reasons for discontinuation or transition. 3. Clinical severity — Chart notes documenting the functional and clinical impact of untreated or undertreated hypogonadism on this patient (fatigue, bone density concerns, sexual health, quality of life, comorbidities). 4. Prescriber medical-necessity letter — A detailed letter from the treating physician that maps the patient's documented clinical findings to each of Humana's stated coverage criteria for testosterone therapy. The letter must reference the FDA-approved prescribing label's indication and the applicable Endocrine Society clinical practice guideline (by organization name, not specific numbers). 5. Humana coverage policy — Obtain the current version of Humana's medical/coverage policy for testosterone replacement therapy (available via Humana's provider portal or on written request). Build the appeal argument around every criterion listed.

## Criteria-Mapping Structure

This is the most important structural element of the appeal. Create a table:

| Humana Coverage Criterion | Documentation Provided | |---|---| | [Criterion 1 from policy] | [Exact chart fact + date + provider] | | [Criterion 2 from policy] | [Exact chart fact + date + provider] | | [Criterion 3 from policy] | [Relevant lab/note] |

Address every criterion — not just the ones you are confident about. Gaps in the mapping table are what reviewers use to uphold denials.